HECTH9 (AX8D1) Mouse mAb #5695
Filter:
- WB
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 482 |
| Source/Isotype | Mouse IgG1 |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
HECTH9 (AX8D1) Mouse mAb recognizes endogenous levels of total HECTH9 protein.
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to human HECTH9 protein.
Background
The HECT domain-containing ubiquitin E3 ligase HECTH9 (also known as HUWE1, ARF-BP1, URE-B1, Mule, and LASU1) is critical for the ubiquitination and proteasomal degradation of many target proteins, and is involved in the regulation of a variety of cellular processes, including DNA replication and base excision repair, cellular proliferation, differentiation, and apoptosis. HECTH9 contains two Armadillo (ARM) repeat-like domains (ARLD1 and ARLD2), a ubiquitin-associated (UBA) domain, a WWE domain, a well-conserved BH3 domain, and a catalytic HECT domain that facilitates ubiquitination of target proteins. HECTH9 has been shown to polyubiquitinate p53 (1,2), Miz1 (3), N-Myc (4,5), Mcl-1 (6), Cdc 6 (7), and DNA polymerase beta (8) through K48-mediated linkage, thereby targeting these proteins for proteosomal degradation. The tumor suppressor protein ARF (known as p14 ARF in humans and p19 ARF in mice) binds to and inhibits the uibiquitin ligase activity toward p53, resulting in stabilization of p53 and induction of apoptosis (1). HECTH9 has also been shown to polyubiquitinate c-Myc through K63-linkage, which is required for recruitment of p300, activation of c-Myc target genes, and induction of cellular proliferation (9). HECTH9 is overexpressed in colon, lung, and breast cancer (1,9). In addition, defects in HECTH9 result in mental retardation syndromic X-linked Turner type (MRXST) and mental retardation X-linked type 17 (MRX17) syndromes (10).
- Chen, D. et al. (2005) Cell 121, 1071-83.
- Yoon, S.Y. et al. (2005) Biochem Biophys Res Commun 326, 7-17.
- Yang, Y. et al. (2010) Proc Natl Acad Sci U S A 107, 13444-9.
- Zhao, X. et al. (2008) Nat Cell Biol 10, 643-53.
- Zhao, X. et al. (2009) Dev Cell 17, 210-21.
- Zhong, Q. et al. (2005) Cell 121, 1085-95.
- Hall, J.R. et al. (2007) Mol Biol Cell 18, 3340-50.
- Parsons, J.L. et al. (2009) EMBO J 28, 3207-15.
- Adhikary, S. et al. (2005) Cell 123, 409-21.
- Froyen, G. et al. (2008) Am J Hum Genet 82, 432-43.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.